Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Translarna ataluren Cancelled
TBD Trastuzumab Cancelled
Truxima Rituximab Cancelled
Atriance Nelarabine Cancelled
Demylocan Decitabine CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Beleodaq Belinostat Withdrawn
Blincyto Blinatumomab Withdrawn
Xospata Gilteritinib Reimburse with clinical criteria and/or conditions Complete
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
TBD Rituximab Cancelled